Targeting C-reactive protein for the treatment of cardiovascular disease.
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement, increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively. Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement. Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP. Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Heuristics may lead to bias or predictable and systematic cognitive errors, as described in Table 2.16,35”
From Artificial Intelligence and Surgical Decision-making. (2020) · cites this paper as [54]
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MOLREP: an Automated Program for Molecular Replacement
Vagin, A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,714
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Self-citationWHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Self-citationThe integration of macromolecular diffraction data
Leslie, A. G. W. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905039107 · Cited by 1,341
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818
Self-citation
Cited by
Items 301–400 of 670
Zhao, J., Liu, J., Pang, X., Wang, S., Wu, D., Zhang, X., & Feng, L. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000354461 · Cited by 31
Denard, J., Marolleau, B., Jenny, C., Rao, T. N., Fehling, H. J., Voit, T., & Svinartchouk, F. (2013) · Journal of Virology · doi:10.1128/jvi.01813-13 · Cited by 31
“Even if substantial functional differences exist between human and animal proteins (42), the evolutionary conservation of sequence presumes similar subunit organizations and protein folds (43).”
BackgroundIsraelsson, E., Ekström, M., Nasr, A., Dolo, A., Kearsley, S., Arambepola, G., Homann, M. V., Maiga, B., Doumbo, O. K., ElGhazali, G. E., et al. (2009) · Malaria Journal · doi:10.1186/1475-2875-8-136 · Cited by 33
“Further research on the effect of CRP on malaria susceptibility is warranted, since recent studies on new therapeutic agents, that lower the circulating CRP levels [45], might open up new adjunct treatment options against malaria.”
BackgroundMay, A., & Wang, T. J. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.6.793 · Cited by 33
IL-6, a central acute-phase mediator, as an early biomarker for exposure to zinc-based metal fumes
Baumann, R., Joraslafsky, S., Markert, A., Rack, I., Davatgarbenam, S., Kossack, V., Gerhards, B., Kraus, T., Brand, P., & Gube, M. (2016) · Toxicology · doi:10.1016/j.tox.2016.11.001 · Cited by 31
Immunosensors for C-Reactive Protein Based on Ultrathin Films of Carboxylated Cellulose Nanofibrils
Zhang, Y., & Rojas, O. J. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b01681 · Cited by 32
Noone, D. P., Isendoorn, M. M. E., Hamers, S. M. W. R., Keizer, M. E., Wulffelé, J., van der Velden, T. T., Dijkstra, D. J., Trouw, L. A., Filippov, D. V., & Sharp, T. H. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404542121 · Cited by 32
“CRP is a target for therapeutic intervention ( 5 , 70 ), and the structure of this immunologically pivotal complex presented herein may provide future routes for targeting CRP for therapeutic purposes.”
Battle of the Biomarkers of Systemic Inflammation
Stec‐Martyna, E., Wojtczak, K., Nowak, D., & Stawski, R. S. (2025) · Biology · doi:10.3390/biology14040438 · Cited by 37
“Moreover, pre-analytical technical errors in cfDNA measurement can arise from delayed processing (at room temperature), as prolonged storage promotes leukocyte lysis and genomic DNA contamination [44,45].”
Morroniside on anti-inflammation activities in rats following acute myocardial infarction
Yu, B., Zhang, G., An, Y., & Wang, W. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2018.22.1.17 · Cited by 30
“Large infarct size increased immediate morbidity and mortality and, in rats that survived this acute event, larger non functional scars adversely affect longterm prognosis [14].”
BackgroundTherapeutic implications of small interfering RNA in cardiovascular diseases
Raghunathan, S., & Patel, B. M. (2012) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2012.01051.x · Cited by 31
Specific Removal of C-Reactive Protein by Apheresis in a Porcine Cardiac Infarction Model
Slagman, A. C., Bock, C., Abdel‐Aty, H., Vogt, B., Gebauer, F., Janelt, G., Wohlgemuth, F., Morgenstern, R., Yapici, G., Puppe, A., et al. (2010) · Blood Purification · doi:10.1159/000320763 · Cited by 30
“However, there is still a controversy whether CRP is only a marker or a risk factor, contributing causative to myocardial damage after AMI.In rats, administration of human CRP after ligation of the coronary artery reproducibly enhanced infarct size by up to 40p [ ,”
BackgroundShould C-Reactive Protein Be a Target of Therapy?
Oh, J., Teoh, H., & Leiter, L. A. (2011) · Diabetes Care · doi:10.2337/dc11-s211 · Cited by 29
“Further studies are warranted to better define the potential clinical utility of directly targeting CRP for the prevention and treatment of CV disease (42).”
BackgroundDoni, A., D’Amico, G., Morone, D., Mantovani, A., & Garlanda, C. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.07.026 · Cited by 30
Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine
Anwaruddin, S., Askari, A. T., & Topol, E. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.051 · Cited by 30
“A ecent study in mice with experimental MI showed that CRP nhibition could markedly reduce infarct size (95).”
BackgroundToth, P. P., McCullough, P. A., Wegner, M. S., & Colley, K. J. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.18 · Cited by 29
SLEVIN, M. A., Heidari, N., & Azamfirei, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.866379 · Cited by 30
“first demonstrated that 1, 6-bis(phosphocholine)-hexane was a small molecule capable of binding in a ration of 5:2 with individual subunits of CRP; on binding, and applied to a rat model of myocardial infarction, both myocardial infarction volume and cardiac dysfunction were abrogated (32).”
BackgroundEffect of Hyperglycemia and Insulin in Acute Coronary Syndromes
Dandona, P., Chaudhuri, A., Ghanim, H., & Mohanty, P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.004 · Cited by 31
Ahmed, U. K., Maller, N. C., Iqbal, A. J., Al‐Riyami, L., Harnett, W., & Raynes, J. G. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.702746 · Cited by 29
“The use of a bisphosphocholine small molecule that complexes CRP was shown to reduce inflammation and complement mediated damage by depleting CRP (55).”
BackgroundKrintus, M., Koziński, M., Stefańska, A., Sawicki, M., Obońska, K., Fabiszak, T., Kubica, J., & Sypniewska, G. (2012) · Mediators of Inflammation · doi:10.1155/2012/419804 · Cited by 29
“Finally, it remains an unsolved issue whether CRP directly contributes to atherothrombotic events and may be a potential therapeutic target, or if it just reflects an increased risk for unfavourable outcome as a bystander marker [8, 9].”
BackgroundThe acute phase response in children with mild and severe malaria in Papua New Guinea.
O’Donnell, A., Fowkes, F., Allen, S., Imrie, H. J., Alpers, M., Weatherall, D., & Day, K. (2009) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2009.03.023 · Cited by 33
C-reactive protein: a marker or a player?
Nyström, T. (2007) · Clinical Science · doi:10.1042/cs20070121 · Cited by 28
“Although simple measurements of white blood cell count and its relationship to CVD have been reported [3], the most promising is CRP as a putative prognostic and predictive marker for cardiovascular events.”
BackgroundInfluentialKomatsu, M., Ohfusa, H., Aizawa, T., & Hashizume, K. (2007) · Endocrine Journal · doi:10.1507/endocrj.k07-032 · Cited by 28
“Namely, human CRP binds to the ligand expressed in damaged tissue leading to activation of compliments [31, 32], and attenuation of CRP action as a possible therapeutic option for cardiovascular disorders is proposed [33].”
BackgroundThe Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP?
Ridker, P. M. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.168989 · Cited by 32
Platelets Affect the Structure and Function of C-Reactive Protein
Filep, J. G. (2009) · Circulation Research · doi:10.1161/circresaha.109.202010 · Cited by 34
Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity
Ullah, N., & Wu, Y. (2022) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-022-01089-x · Cited by 30
“Moreover, 1,6 bisphosphocholine (bisPC), a small molecule CRP inhibitor that crosslinks two pentameric CRP by attaching to the phosphocholine binding site, can prevent pCRP dissociation and reduce CRP-induced myocardial damage [12, 128].”
BackgroundNeurokinin 3 Receptor and Phosphocholine Transferase
Parchim, N. F., Wang, W., Iriyama, T., Ashimi, O. A., Siddiqui, A. H., Blackwell, S. C., Sibai, B. M., Kellems, R. E., & Xia, Y. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04439 · Cited by 27
“Although the transient elevation of CRP in response to the presence of pathogens is beneficial, the prolonged and persistent elevation of CRP is likely harmful resulting in damage to host tissues.(4,5,7,10,21,22) Some studies have suggested that obesity and increasing body mass index, correlated with late-onset preecl…”
BackgroundDu, T., & Tan, Z. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20143695 · Cited by 27
“Pepys announced that their new compound (1,6-bis(phosphocholine)-hexane) could inhibit the damage to an organism caused by CRP, and as a result could reduce the risk of cardiac events, and myocardial infarction, in particular (15).”
BackgroundMicroRNAs in Cerebral Ischemia
Lim, K.-Y., Chua, J.-H., Tan, J.-R., Swaminathan, P., Sepramaniam, S., Armugam, A., Wong, P. T.-H., & Jeyaseelan, K. (2010) · Translational Stroke Research · doi:10.1007/s12975-010-0035-3 · Cited by 29
“A recent study demonstrated that antagonizing Crp improves the outcome after experimental myocardial infarction [56].”
BackgroundPentraSorb C‐Reactive Protein: Characterization of the Selective C‐Reactive Protein Adsorber Resin
Mattecka, S., Brunner, P., Hähnel, B., Kunze, R., Vogt, B., & Sheriff, A. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12796 · Cited by 27
High serum CRP influences myocardial miRNA profiles in ischemia-reperfusion injury of rat heart
Kim, E. N., Kim, C. J., Kim, S. R., Song, J.-A., Choe, H., Kim, K., Choi, J. S., & Oh, S. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216610 · Cited by 27
Jia, H., Qu, M., Fan, G., Wu, H., & Wang, L. (2019) · Neuroscience Research · doi:10.1016/j.neures.2019.12.002 · Cited by 27
Kayser, S., Brunner, P., Althaus, K., Dorst, J., & Sheriff, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092947 · Cited by 29
“Specifically, targeting avoidable organ damage caused by the action of CRP represents a promising therapeutic option [43,53].”
BackgroundSolheim, S., Seljeflot, I., Lunde, K. B., Aukrust, P., Yndestad, A., Grøgaard, H. K., Aakhus, S., Forfang, K., & Arnesen, H. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.10.005 · Cited by 29
Iwasaki, S., Kawasaki, H., & Iwasaki, Y. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b01007 · Cited by 26
The acute phase response and C-reactive protein
Pepys, M. B. (2020) · doi:10.1093/med/9780198746690.003.0239 · Cited by 27
Self-citationWang, Q., Peng, K., Gan, N., Liu, X., Huang, H., Shao, H., Jin, H., Crommen, J., & Jiang, Z. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.125121 · Cited by 25
von Eckardstein, A., & Binder, C. J. (2022) · Handbook of experimental pharmacology · doi:10.1007/978-3-030-86076-9 · Cited by 42
Rogowski, O., Shapira, I., Steinvil, A., & Berliner, S. A. (2009) · Metabolism · doi:10.1016/j.metabol.2009.01.005 · Cited by 26
“There are multiple lines of evidence to suggest a role for hs-CRP as an effector of the atherosclerotic [23] and thrombotic [24] disease, suggesting that it might not necessarily be an innocent bystander in the cardiovascular”
BackgroundUeba, H., Shiomi, M., Brines, M. L., Yamin, M., Kobayashi, T., Ako, J., Momomura, S., Cerami, A., & Kawakami, M. (2013) · Molecular Medicine · doi:10.2119/molmed.2013.00037 · Cited by 25
Regulation of cell function by isoforms of C-reactive protein: a comparative analysis.
Boncler, M. A., & Watała, C. W. (2009) · Acta Biochimica Polonica · doi:10.18388/abp.2009_2513 · Cited by 27
Metal-Organic frameworks for optical sensor arrays
Zhang, X., Cui, Y., & Qian, G. (2025) · Progress in Materials Science · doi:10.1016/j.pmatsci.2025.101507 · Cited by 30
C‐reactive protein: an independent predictor of cardiovascular disease in Aboriginal Australians
Wang, Z., & Hoy, W. E. (2010) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2010.00548.x · Cited by 25
“designed a specific small-molecule CRP inhibitor that blocks the adverse effects of human CRP in rats with acute myocardial infarction.(25) Their study suggests that early therapeutic inhibition of CRP might be beneficial for heart attack patients.”
BackgroundTargeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
Torzewski, J., Brunner, P., Ries, W., Garlichs, C. D., Kayser, S., Heigl, F., & Sheriff, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071771 · Cited by 26
“• CRP inhibition by antisense technologies [83]; • CRP inhibition by small molecular weight inhibitors [84]; • Inhibition of hepatic CRP synthesis [85]; • Inhibition of CRP mediated complement activation; • Inhibition of CRP binding to its receptors.”
BackgroundShould patients with rheumatoid arthritis receive statin therapy?
Ridker, P. M., & Solomon, D. H. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24521 · Cited by 25
Is there a role of C ‐reactive protein in red blood cell aggregation?
Flormann, D., Kuder, E., Lipp, P., Wagner, C., & Kaestner, L. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12313 · Cited by 25
“gated the increase in infarct size and cardiac dysfunction produced by injection of human CRP [6].”
BackgroundKokorina, A. A., Ponomaryova, Т. S., & Goryacheva, I. Y. (2020) · Talanta · doi:10.1016/j.talanta.2020.121837 · Cited by 23
Affinity of C-Reactive Protein toward FcγRI Is Strongly Enhanced by the γ-Chain
Röcker, C., Manolov, D., Kuzmenkina, E. V., Tron, K., Slatosch, H., Torzewski, J., & Nienhaus, G. U. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060734 · Cited by 27
Cardiovascular Biomarkers: Current Status and Future Directions
Filipovic, M. G., & Luedi, M. M. (2023) · Cells · doi:10.3390/cells12222647 · Cited by 23
Pattern Recognition Proteins: First Line of Defense Against Coronaviruses
Labarrere, C. A., & Kassab, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652252 · Cited by 24
Monomeric C‑reactive protein level is associated with osteoarthritis
Liang, Y., Xu, K., Liu, W., Liu, X., Yuan, P., Xu, P., & Li, H. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11206 · Cited by 22
“In myocardial infarction, for example, CRP mediates tissue damage mainly by activating complement pathways (31,32).”
BackgroundBurel, S. A., Machemer, T., Baker, B. F., Kwoh, T. J., Paz, S., Younis, H. S., & Henry, S. P. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0033 · Cited by 23
Inflammasomes: Cause or consequence of obesity‐associated comorbidities in humans
Herrera-Martínez, A. D., Herrero‐Aguayo, V., Pérez‐Gómez, J. M., Gahete, M. D., & Luque, R. M. (2022) · Obesity · doi:10.1002/oby.23581 · Cited by 23
“Specifically, CRP has been described as a strong factor associated with overweight and obesity in humans; some additional functional roles of this inflammation marker also have been suggested [18, 19], and its chronic elevation has even been suggested”
BackgroundThe effect of Aloe vera leaf gel on fatty streak formation in hypercholesterolemic rabbits.
Dana, N., Javanmard, S. H., Asgary, S., Asnaashari, H., & Abdian, N. (2012) · Europe PMC (PubMed Central) · Cited by 22
Labarrere, C. A., Woods, J. R., Hardin, J. W., Jaeger, B. R., Zembala, M., Deng, M. C.-H. K., & Kassab, G. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113260 · Cited by 23
“The involvement of CRP in arterial vasculopathy of transplanted hearts points to the possibility of using these molecules as therapeutic targets [46] to block or delay disease development or progression.”
BackgroundTargeting BNIP3 in inflammation-mediated heart failure: a novel concept in heart failure therapy
Asare, P. F., Wang, L., Gao, H., Li, L., Wang, Y., Nyagblordzro, M., Agyemang, K., & Fan, G. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9557-4 · Cited by 24
Immunosensor for electrodetection of the C-reactive protein in serum
Resende, L. O., de Castro, A. C. H., Andrade, A. D. O., Madurro, J. M., & Brito‐Madurro, A. G. (2017) · Journal of Solid State Electrochemistry · doi:10.1007/s10008-017-3820-z · Cited by 22
Świątkiewicz, I., Koziński, M., Magielski, P., Gierach, J., Fabiszak, T., Kubica, A., Sukiennik, A., Navarese, E. P., Odrowąż‐Sypniewska, G., & Kubica, J. (2012) · Inflammation Research · doi:10.1007/s00011-012-0466-2 · Cited by 22
“Finally, it remains an unsolved issue whether CRP directly contributes to post-infarct LVSD and may be a potential therapeutic target, or if it just reflects an increased risk for unfavourable outcome as a bystander marker [29, 30].”
BackgroundAnti-Monomeric C-Reactive Protein Antibody Ameliorates Arthritis and Nephritis in Mice
Fujita, C., Sakurai, Y., Yasuda, Y., Takada, Y., Huang, C.-L., & Fujita, M. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100349 · Cited by 21
Cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes
Kolkhof, P., Geerts, A., Schäfer, S., & Torzewski, J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.177 · Cited by 23
Roubille, F., Cayla, G., Picot, M., Pradet, V., Massin, F., Gervasoni, R., Pasquie, J.-L., Macia, J.-C., Piot, C. A., & Leclercq, F. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.01.026 · Cited by 23
Tegler, L. T., Nonglaton, G., Büttner, F., Caldwell, K. D., Christopeit, T., Danielson, U. H., Fromell, K., Gossas, T., Larsson, A. O., Longati, P., et al. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201005059 · Cited by 21
Melnikov, I., Kozlov, S. G., Saburova, O., Zubkova, E., Гусева, О. А., Domogatsky, S. P., Arefieva, T. I., Radyukhina, N. V., Zvereva, M. D., Avtaeva, Y., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8100435 · Cited by 21
“Also, the presence of negatively charged phospholipids, especially phosphatidylcholine, is a prerequisite for pCRP dissociation into mCRP subunits [12,25].”
BackgroundC-Reactive Protein Enhances IgG-Mediated Cellular Destruction Through IgG-Fc Receptors in vitro
Temming, A. R., Buirs, M. T., Bentlage, A. E. H., Treffers, L. W., Feringa, H., de Taeye, S. W., Kuijpers, T. W., Nagelkerke, S. Q., Brasser, G., Mok, J. Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.594773 · Cited by 21
C-reactive protein levels are associated with the progression of atherosclerotic lesions in rabbits.
Yu, Q., Li, Y., Wang, Y., Zhao, S., Yang, P., Chen, Y., Fan, J., & Liu, E. (2012) · PubMed · doi:10.14670/hh-27.529 · Cited by 21
Wang, H., Chen, D.-L., Zhao, M., Shu, S.-W., Xiong, S., Gan, X., Chao, S.-P., & Cao, J. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000332402 · Cited by 22
Karpiński, Ł., Płaksej, R., Derzhko, R., Orda, A., & Witkowska, M. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.624 · Cited by 21
Targeting the Unstable Plaque in Acute Coronary Syndromes
Thompson, P. L., Nidorf, S. M., & Eikelboom, J. W. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.332 · Cited by 20
Manganese-Enhanced T1 Mapping in the Myocardium of Normal and Infarcted Hearts
Spath, N., Lilburn, D. M. L., Gray, G. A., Page, L. M. L., Papanastasiou, G., Lennen, R. J., Janiczek, R. L., Dweck, M. R., Newby, D. E., Yang, P. C.-M., et al. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/9641527 · Cited by 20
“Myocardial infarction was induced as we have previously described [27].”
MethodSelf-citationvan Leuven, S. I., Birjmohun, R. S., Franssen, R., Bisoendial, R. J., de Kort, H., Levels, J. H. M., Basser, R., Meijers, J. C. M., Kuivenhoven, J. A., Kastelein, J. J. P., et al. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03175.x · Cited by 20
New biochemical markers: From bench to bedside
Zaninotto, M., Mion, M. M., Novello, E., Altinier, S., & Plebani, M. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.02.028 · Cited by 20
From Homeostasis To Inflammation To Autoimmunity: The Potential Impact of CRP
Ahmed, M. J., Yuan, P., Lei, J.-G., Tang, Z.-M., Yang, Z.-R., Potempa, L. A., Wang, H., & Li, H. (2025) · Inflammation · doi:10.1007/s10753-025-02303-7 · Cited by 23
“Striking this delicate balance is essential, ensuring that the interventions not only attenuate the pro-inflammatory actions but also preserve CRP’s effectiveness in modulating the immune response [35, 41, 213, 228].”
Lechner, I., Reindl, M., Tiller, C., Holzknecht, M., Fink, P., Troger, F., Angerer, G., Angerer, S. V., Henninger, B., Mayr, A., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028932 · Cited by 19
C-Reactive Protein: An Important Inflammatory Marker of Coronary Atherosclerotic Disease
Zhao, X., Cheng, G., Chen, H., Chen, X., Liu, T., & Gu, D. (2024) · Angiology · doi:10.1177/00033197241273360 · Cited by 22
“105 In vitro experiments con fi rmed that the injection of 1,6-bis-PC to AMI rats indeed eliminated the increase in infarction area and cardiac disorder induced by human CRP, providing a new option for the treatment of patients with MI.”
Feng, J.-R., Li, X., Han, C., Chang, Y., Fu, Y., Feng, G.-C., Lei, Y., Li, H., Tang, P. M., Ji, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0253 · Cited by 20
Xia, M. X., Zhang, C., Gu, J., Chen, J., Wang, L., Lu, Y., Huang, C., He, Y., & Yang, X. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.02.025 · Cited by 19
In vitro generation and bioactivity evaluation of C-reactive protein intermediate
Lv, J., & Wang, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198375 · Cited by 19
Targeting protein self-association in drug design
Thabault, L., Liberelle, M., & Frédérick, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.028 · Cited by 19
C-Reactive protein-directed immobilization of phosphocholine ligands on a solid surface
Kim, E., Kim, H.-C., Lee, S. G., Lee, S. J., Go, T.-J., Baek, C. S., & Jeong, S. W. (2011) · Chemical Communications · doi:10.1039/c1cc15079k · Cited by 19
Gray, G. A., Patrizio, M., Sherry, L., Miller, A. A., Malaki, M., Wallace, A. F., LEIPER, J. M., & Vallance, P. J. (2009) · Acta Histochemica · doi:10.1016/j.acthis.2009.02.009 · Cited by 19
Self-citationHo, K. J., Owens, C. D., Longo, T. A., Sui, X., Ifantides, C., & Conte, M. S. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00079.2008 · Cited by 19
“Although we established a dose-dependent increase in PDGFR expression and phosphorylation and PDGF-BB-mediated chemotaxis with CRP treatment of HSV SMCs, neither CRP blocking antibodies (16, 28) nor the specific small-molecule inhibitor of CRP (43) was available to us to confirm the specificity of our interaction.”
Belló-Pérez, M., Falcó, A., Medina-Gali, R. M., Encinar, J. A., Novoa, B., Pérez, L., Estepa, A., & Coll, J. M. (2016) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2016.12.001 · Cited by 19
“Therefore it has been widely used as a biomarker for inflammation (Pepys et al., 2006).”
MethodRole of Thromboxane Receptor in C-Reactive Protein–Induced Thrombosis
Grad, E., Pachino, R. M., FitzGerald, G. A., & Danenberg, H. D. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.256073 · Cited by 18
“Furthermore, in vivo studies demonstrated that CRP is prothrombotic(15,24) and augments myocardial infarction severity.(25) A possible pathway for CRP prothrombotic activity is the prostanoid pathway.”
BackgroundBiomarkers in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Müller-Stich, B. P., & Tamm, M. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200607-922ed · Cited by 18
Risk of type 2 diabetes mellitus in those with hypertension
Das, U. N. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn037 · Cited by 19
Khalafi, M., Maleki, A. H., Symonds, M. E., Alamdari, K. A., Ehsanifar, M., & Rosenkranz, S. K. (2025) · Obesity Reviews · doi:10.1111/obr.13954 · Cited by 18
“CRP is an acute-phase reactant primarily produced by the liver in response to a variety of pro-inflammatory cytokines including IL-6 and TNF-α and has been widely used in the diagnosis and management of chronic diseases [158–161].”
Regulated conformation changes in C-reactive protein orchestrate its role in atherogenesis
Ma, X., Ji, S., & Wu, Y. (2012) · Chinese Science Bulletin · doi:10.1007/s11434-012-5591-3 · Cited by 18
C‐reactive protein and incident hypertension in a worksite population of Japanese men
Kansui, Y., Matsumura, K., Morinaga, Y., Inoue, M., Kiyohara, K., Ohta, Y., Gotō, K., Ohtsubo, T., Ooboshi, H., & Kitazono, T. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13510 · Cited by 17
Süleymanoğlu, M., Burak, C., Gümüşdağ, A., Yesın, M., Rencüzoğulları, İ., Karabağ, Y., Çağdaş, M., & Çap, M. (2020) · Vascular · doi:10.1177/1708538120925952 · Cited by 17
“CRP may not only be associated with vascular inflammatory reactions but also may facilitate atherogenesis and atherothrombosis.(18,19) Although the exact mechanism is not fully understood, pathogenesis of CRP and atherosclerotic severity are attributed to certain mechanisms.”
BackgroundNoone, D. P., van der Velden, T. T., & Sharp, T. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757633 · Cited by 19
“Art ific ia l decamerization of CRP, via the B-face, using a bivalent PCh analogue showed promise as a therapeutic to inhibit CRP binding and treat cardiovascular and inflammatory diseases (48).”
CRP in cerebrovascular stroke: Prognostic implications
Shoaeb, M. A., Shehata, M. R., Taema, K., & Hammouda, M. A. (2014) · The Egyptian Journal of Critical Care Medicine · doi:10.1016/j.ejccm.2014.03.001 · Cited by 18
“Interestingly, studies have shown that CRP itself may contribute to secondary brain damage after focal cerebral ischemia, possibly via a complement-mediated exacerbation of tissue injury [36].”
Kurotobi, T., Iwakura, K., Inoue, K., Kimura, R., Okamura, A., Koyama, Y., Toyoshima, Y., Ito, N., & Fujii, K. (2010) · EP Europace · doi:10.1093/europace/euq155 · Cited by 17
Singh, P., Singh, M., Nagpal, H. S., Kaur, T., Khullar, S., Kaur, G., Dhillon, H., Napoli, M. D., & Mastana, S. S. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3459-0 · Cited by 18
Krivoy, N., Adler, Z., Saloma, R., Hawadie, A., & Azzam, Z. S. (2008) · Europe PMC (PubMed Central) · Cited by 17
Rogowski, O., Shapira, I., Peretz, H., & Berliner, S. A. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03017.x · Cited by 17
Maharshak, N., Arbel, Y., Gal‐Oz, A., Rogowski, O., Shapira, I., Berliner, S. A., Vered, Y., Canaani, J., & Dotan, I. (2008) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2008.00335.x · Cited by 17
Hwang, J., Wu, T., Chou, S. C., Ho, C. L., Chang, P.-Y., Tsao, K., Huang, J., Sun, C., & Wu, J. T. (2008) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.20207 · Cited by 21
“CRP, for example, is proinflammatory (32,33).”
Stampfl, S., Stampfl, U., Bellemann, N., Radeleff, B. A., López-Benítez, R., Sommer, C.-M., Thierjung, H., Berger, I., & Richter, G. M. (2009) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2009.03.040 · Cited by 18
“CRP-induced exacerbation of ischemic necrosis in a complement-dependent fashion has been reported (36).”
BackgroundC reactive protein and the risk of cardiovascular disease
Keavney, B. D. (2011) · BMJ · doi:10.1136/bmj.d144 · Cited by 18
“So, where does that leave CRP? This marker is definitely associated with the risk of coronary heart disease, although it is unlikely to be causal. In future, clinical trials of recently discovered specific CRP antagonists or very low dose methotrexate that would reduce inflammation but not affect other risk factors fo…”
BackgroundQian, S., Zhang, S., Chen, D., Wang, J., Wu, W., Zhang, S., Geng, Z. H., He, Y. W., & Zhu, B. (2023) · Polymers · doi:10.3390/polym15183739 · Cited by 16
“After that, Parylene C layer with a thickness of 3 μm was deposited to encapsulate the gold interconnecting lanes from dichloro-[2,2]-paracyclophane (Saen Chemical Technology Co.”
BackgroundMethodThe pentraxin family in autoimmune disease
Li, Y., Zhang, S., Liu, J., Zhang, N., Zhang, N., Cheng, Q., Zhang, H., & Wu, X. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117592 · Cited by 19
Metadata
- Authors
- Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., Cobb, A. J. A., Ley, S. V., Andrew Aquilina, J., Robinson, C. V., Sharif, I., Gray, G. A., Sabin, C. A., Jenvey, M. C., Kolstoe, S. E., Thompson, D., & Wood, S. P.
- Affiliations
- The Royal Free Hospital (GB)
- University of Pavia (IT)
- University of Cambridge (GB)
- University of Edinburgh (GB)
- University of Southampton (GB)
- University of Sussex (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Nature
- Published
- 2006-04
- Volume
- 440
- Issue
- 7088
- Pages
- 1217-1221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2080883999
- Cited by
- 672
- References
- 31
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 30 · 2022: 27 · 2021: 28 · 2020: 32 · 2019: 21 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 16 · 2014: 35 · 2013: 30 · 2012: 40
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- C-reactive protein, acute myocardial infarction, complement activation, cardioprotection, infarct size, neuroprotection, cerebral ischemia, small-molecule drug design, acute phase proteins, inflammation, stroke, drug repurposing
- MeSH terms
- Animals, C-Reactive Protein, Cardiovascular Diseases, Complement System Proteins, Hexanes, Humans, Male, Models, Molecular, Molecular Conformation, Myocardial Infarction, Phosphorylcholine, Drug Design, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.